Concepedia

Kathleen A. Bridges

KA

8

Publications

509

Citations

8

H-Index

2009

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

UPMC Hillman Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Baylor College of Medicine

Gwynedd Mercy University

Kathleen A. Bridges is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, redox biology, and molecular oncology.

Top concepts

Publications per year

2009–2021

8

Publications

8

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

Kathleen A. Bridges, Hiroshi Hirai, Carolyn A. Buser et al. · Clinical Cancer Research · 2011 · 231 citations · Full text

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells

Kathleen A. Bridges, Carlo Toniatti, Carolyn A. Buser et al. · Oncotarget · 2014 · 55 citations · Full text

Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints

Jessica M. Molkentine, David Molkentine, Kathleen A. Bridges et al. · International Journal of Radiation Biology · 2020 · 41 citations · Full text

ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress

Adrienne Howard, Kathleen A. Bridges, Raymond E. Meyn et al. · Cancer Chemotherapy and Pharmacology · 2009 · 38 citations

, , +4

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Colin Brooks, Tommy Sheu, Kathleen A. Bridges et al. · Radiation Oncology · 2012 · 37 citations · Full text

Rows per page

1–5 of 8